Meeting
2023 ASCO Annual Meeting
Patient perspectives on BCMA-targeted therapies for multiple myeloma: A survey conducted in a patient advocacy group.
Authors
Jennifer M. Ahlstrom
HealthTree Foundation, Lehi, UT
Jennifer M. Ahlstrom , Dee Lin , Nathan W. Sweeney , Bingcao Wu , Katharine Gries , Nina Kim , Saurabh Patel , Douglas W. Sborov , Jesus G. Berdeja , Larry D. Anderson, Jr , Jinhai Huo , Jay R Hydren
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Developmental Therapeutics—Immunotherapy
Track
Developmental Therapeutics—Immunotherapy
Sub Track
New Targets and New Technologies (IO)
Citation
J Clin Oncol 41, 2023 (suppl 16; abstr 2582)
DOI
10.1200/JCO.2023.41.16_suppl.2582
Abstract #
2582
Poster Bd #
424
Abstract Disclosures
Similar Posters
Poster
2022 ASCO Annual Meeting
Real-world analysis of safety and efficacy of CAR T-cell therapy in patients with lymphoma with decreased renal function.
First Author: Omar Mamlouk
Poster
2019 ASCO-SITC Clinical Immuno-Oncology Symposium
Preclinical CAR-T cell target safety, biodistribution, and tumor infiltration analysis using in situ hybridization technology.
First Author: Helly Pimentel
Poster
2018 ASCO Annual Meeting
Which is better in CD19 CAR-T treatment of r/r B-ALL, CD28 or 4-1BB? A parallel trial under the same manufacturing process.
First Author: Peihua Lu
Poster
2024 ASCO Breakthrough
Hypoxia-responsive synthetic gene circuits to improve safety and potency of CAR T cell therapy for solid tumors.
First Author: Yannick Schreiber